Top-Rated StocksTop-RatedNASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis $27.79 -0.29 (-1.03%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$27.80 +0.02 (+0.05%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amylyx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$27.64▼$28.8150-Day Range$19.49▼$39.6652-Week Range$10.83▼$41.14Volume912,369 shsAverage Volume1.37 million shsMarket Capitalization$3.10 billionP/E RatioN/ADividend YieldN/APrice Target$38.86Consensus RatingBuy Company Overview Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company is advancing a pipeline of investigational therapies across endocrine conditions and neurodegenerative diseases, including avexitide for post-bariatric hypoglycemia, AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis, and AMX0318 for post-bariatric hypoglycemia and other rare diseases. Founded in 2013 by Joshua Cohen and Justin Klee, Amylyx is headquartered in Cambridge, Massachusetts. Cohen and Klee have served as the company’s co-chief executive officers and have led its efforts to advance therapies for diseases with high unmet needs. Read More Amylyx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreAMLX MarketRank™: Amylyx Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat, and ranked 232nd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAmylyx Pharmaceuticals has a consensus price target of $38.86, representing about 39.8% upside from its current price of $27.79.Amount of Analyst CoverageAmylyx Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($1.48) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -19.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -19.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 10.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amylyx Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.61% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 8.64.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 6.09%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.73 News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Amylyx Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,259,057.00 in company stock.Percentage Held by Insiders10.90% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMLX Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Cooper Co (COO), Amylyx Pharmaceuticals Inc (AMLX) and CervoMed (CRVO)October 2 at 2:46 PM | theglobeandmail.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of "Buy" from AnalystsOctober 2 at 2:15 AM | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 4 at 1:00 AM | Profits Run (Ad)Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic ForumSeptember 23, 2026 | marketscreener.comMAmylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Insider Gina Mazzariello Sells 9,536 Shares of StockSeptember 15, 2026 | insidertrades.comAmylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?August 21, 2026 | insidermonkey.comAmylyx Pharmaceuticals Readies for Pivotal LUCIDITY DataAugust 20, 2026 | theglobeandmail.comSee More Headlines AMLX Stock Analysis - Frequently Asked Questions How have AMLX shares performed this year? Amylyx Pharmaceuticals' stock was trading at $12.08 at the start of the year. Since then, AMLX stock has increased by 130.0% and is now trading at $27.79. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) posted its quarterly earnings data on Thursday, August, 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.03. Read the conference call transcript. When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering on Thursday, January 6th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amylyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/06/2026Today10/04/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 AMLX's financial health is in the Green zone, according to TradeSmith. AMLX has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AMLX CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees136Year Founded2013Price Target and Rating Average Price Target for Amylyx Pharmaceuticals$38.86 High Price Target$57.00 Low Price Target$19.00 Potential Upside/Downside+39.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$144.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.92% Return on Assets-48.53% Debt Debt-to-Equity RatioN/A Current Ratio12.12 Quick Ratio12.12 Sales & Book Value Annual Sales$87.37 million Price / Sales35.44 Cash FlowN/A Price / Cash FlowN/A Book Value$2.78 per share Price / Book10.00Miscellaneous Outstanding Shares111,420,000Free Float99,278,000Market Cap$3.10 billion OptionableOptionable Beta-0.10 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:AMLX) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredFree Stock: Economist calls it “the world’s most important machine.”Nvidia's most expensive chip component isn't made by Nvidia. Jeff Brown, former semiconductor executive, says ...Brownstone Research | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
